FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

CADILAHC

358.8
-3.9 (-1.08%)
Updated 03:29 05/06 IST

CADILAHC Buy or Sell - FrontPage Forums

2 Users have submitted 2 trade ideas of Rs. 754,600 for CADILAHC
Disclaimer
100% Bullish
0% Bearish

CADILAHC Ratings

Long term CADILAHC rating by FrontPage users
4.2/5 (19 Ratings)
Find answers to all your questions on live CADILAHC message board: Is CADILAHC buy or sell? Should I buy CADILAHC shares? Why are CADILAHC shares falling? Should I invest in CADILAHC stock?

CADILAHC Share Price Discussion


CADILA HEALTH GOT US FDA FINAL OK FOR GENERIC OF REYATAZ CAPSULES
Like
Reply
Reputation: 3,179 • Today 4:28 AM
ICMR validates three IgG Elisa test kits to be used in sero-survey
The IgG Elisa test kit helps in detecting immunoglobulin class G antibody in the blood samples and determine who had previously been infected with COVID-19 and may have developed an immunity.
Moneycontrol
Like
Reply

Type
Buy
Instrument
CADILAHC JUN20 FUT
Entry Price
₹361.15
Price@Trade
₹361.15
Target Price
₹372.3
Stop Price
₹353
Valid Till
Jun 5, 2020 3:20 AM
Margin
₹206,467.8 approx for 2200 Qty
Status
Exited
Exit Price
₹363.4
Net P&L
+₹4,950 (+2.4%)
Like
Reply (1)
Latest replies

Update
Exited
Exit Price
₹363.4
Net P&L
+₹4,950 (+2.4%)
Like
Reply
Like
Reply
Reputation: 13,291 • Jun 3 3:12 AM

Type
Sell
Instrument
CADILAHC
Entry Price
₹353  ₹352.15
Price@Trade
₹352.55
Target Price
₹348
Stop Price
₹357.5
Valid Till
Jun 3, 2020 3:20 AM
Margin
₹70,430 approx for 200 Qty
Status
Stoploss Hit
Exit Price
₹357.5
Net P&L
-₹1,070 (-1.52%)
Like
Reply (4)
Latest replies
King999 @king999
Jun 3 3:12 AM

Update
Entry Price Modified
Price @ Update
₹352.7
Original Entry Price
₹353
New Entry Price
₹352.7
King999 @king999
Jun 3 3:12 AM

Update
Entry Price Modified
Price @ Update
₹352.15
Original Entry Price
₹352.7
New Entry Price
₹352.15
TrackerBot @trackerbot
Jun 3 3:13 AM

Update
Trade Entered
Entry Price
₹352.15
TrackerBot @trackerbot
Jun 3 3:34 AM

Update
Stoploss Hit
Exit Price
₹357.5
Reputation: 19,103 • Jun 3 3:09 AM

Type
Buy
Instrument
CADILAHC JUN20 350 PE
Entry Price
₹16.7
Price@Trade
₹16.7
Target Price
₹20
Stop Price
₹15
Valid Till
Jun 3, 2020 3:20 AM
Margin
₹36,740 approx for 2200 Qty
Status
Stoploss Hit
Exit Price
₹15
Net P&L
-₹3,740 (-10.18%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Jun 3 3:30 AM

Update
Stoploss Hit
Exit Price
₹15
# ENRICHANSRAJ - PANDEY in CADILAHC
New trade: Sell CADILAHC JUN20 FUT, CMP@355.3, ...
Like
Reply

Type
Sell
Instrument
CADILAHC JUN20 FUT
Entry Price
₹355.5
Price@Trade
₹355.3
Target Price
₹343
Stop Price
₹362
Valid Till
Jun 2, 2020 3:20 AM
Margin
₹207,600.25 approx for 2200 Qty
Status
Exited
Exit Price
₹354.55
Net P&L
+₹2,090 (+1.01%)
Like
Reply (3)
Latest replies
TrackerBot @trackerbot
Jun 2 7:13 AM

Update
Trade Entered
Entry Price
₹355.5

354.5 TILL TIME PROFIT 2200/-

Update
Exited
Exit Price
₹354.55
Net P&L
+₹2,090 (+1.01%)
J
Reputation: -22,725 • Jun 2 7:00 AM

Type
Sell
Instrument
CADILAHC JUN20 FUT
Entry Price
₹356.85
Price@Trade
₹356.85
Target Price
₹340
Stop Price
₹369
Valid Till
Jun 25, 2020 3:20 AM
Margin
₹207,727.3 approx for 2200 Qty
Status
Exited
Exit Price
₹355
Net P&L
+₹4,070 (+1.96%)
Like
Reply (1)
Latest replies
Jsm @JSMConsulting
Jun 2 7:35 AM

Update
Exited
Exit Price
₹355
Net P&L
+₹4,070 (+1.96%)
Reputation: 19,103 • Jun 2 6:42 AM

Type
Sell
Instrument
CADILAHC JUN20 FUT
Entry Price
₹355.8
Price@Trade
₹355.8
Target Price
₹350
Stop Price
₹360
Valid Till
Jun 2, 2020 3:20 AM
Margin
₹202,582 approx for 2200 Qty
Status
Exited
Exit Price
₹356.9
Net P&L
-₹2,420 (-1.19%)
Like
Reply (1)
Latest replies
ProTrader @ProTraderIndia
Jun 2 6:49 AM

Update
Exited
Exit Price
₹356.9
Net P&L
-₹2,420 (-1.19%)

Type
Buy
Instrument
CADILAHC JUN20 400 CE
Entry Price
₹6.35
Price@Trade
₹6.35
Target Price
₹20
Stop Price
₹3
Valid Till
Jun 25, 2020 3:20 AM
Margin
₹13,970 approx for 2200 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
CADILAHC JUN20 360 CE
Entry Price
₹20.5  ₹20.85
Price@Trade
₹20.9
Target Price
₹27
Stop Price
₹15  ₹17.5
Valid Till
Jun 25, 2020 3:20 AM
Margin
₹45,870 approx for 2200 Qty
Status
Stoploss Hit
Exit Price
17.5
Net P&L
-₹7,370 (-16.07%)
Like
Reply (5)
Latest replies

Update
Entry Price Modified
Price @ Update
₹20.8
Original Entry Price
₹20.5
New Entry Price
20.85
TrackerBot @trackerbot
Jun 2 3:59 AM

Update
Trade Entered
Entry Price
20.85

Update
Stoploss Trailed
Price @ Update
₹17.4
Original SL
₹15
New SL
17.0

Update
Stoploss Trailed
Price @ Update
₹17.95
Original SL
₹17
New SL
17.5
TrackerBot @trackerbot
Jun 3 6:17 AM

Update
Stoploss Hit
Exit Price
17.5
Reputation: 3,179 • Jun 2 1:13 AM
Hot Stocks | Apollo Tyres, IOC can give double-digit return in short term
The next resistance for Nifty is seen at 9,970 and 10,550, which happens to be 50 percent and 61.8 percent retracements of the entire fall seen from January 2020 (12,430) to March 2020 (7,511).
Moneycontrol
Like
Reply

Type
Buy
Instrument
CADILAHC JUN20 FUT
Entry Price
₹346.6
Price@Trade
₹346.6
Target Price
₹358
Stop Price
₹339
Valid Till
Jun 2, 2020 3:20 AM
Margin
₹199,828.2 approx for 2200 Qty
Status
Exited
Exit Price
₹348.55
Net P&L
+₹4,290 (+2.15%)
Like
Reply (1)
Latest replies

Update
Exited
Exit Price
₹348.55
Net P&L
+₹4,290 (+2.15%)
A
Reputation: 2,487 • Jun 1 3:53 AM

Type
Buy
Instrument
CADILAHC JUN20 FUT
Entry Price
₹348
Price@Trade
₹347.7
Target Price
₹356
Stop Price
₹340
Valid Till
Jun 1, 2020 3:20 AM
Margin
₹199,912.9 approx for 2200 Qty
Status
Exited
Exit Price
₹349.45
Net P&L
+₹3,190 (+1.6%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jun 1 3:55 AM

Update
Trade Entered
Entry Price
₹348
Anish @anish-SyOlsUcHL
Jun 1 5:19 AM

Update
Exited
Exit Price
₹349.45
Net P&L
+₹3,190 (+1.6%)
Reputation: 2,196 • Jun 1 3:18 AM

Sell Cadilla Hc cash
346-348
Sl 350
Tgt open
Like
Reply (1)
Latest replies
DREAM BIG VIEW @dreambig
Jun 1 3:27 AM

347.5 to 344.5
Reputation: 3,179 • May 29 6:38 AM
Building portfolio: Experts bet on 21 scrips to create wealth in coming years
Aashish Somaiyaa of Motilal Oswal Asset Management Company advised that one should avoid panic and remain invested.
Moneycontrol
Like
Reply
Reputation: 6,068 • May 29 3:26 AM

Type
Buy
Instrument
CADILAHC JUL20 FUT
Entry Price
₹350  ₹349.85
Price@Trade
₹350.3
Target Price
₹355.65
Stop Price
₹347.1
Valid Till
May 29, 2020 3:20 AM
Margin
₹203,753 approx for 2200 Qty
Status
Stoploss Hit
Exit Price
₹347.1
Net P&L
-₹6,050 (-2.97%)
buy cadilac above 350 target 355.65-360.2-365 stoploss 347.1
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
May 29 3:38 AM

Update
Trade Entered
Entry Price
₹349.85
TrackerBot @trackerbot
May 29 4:02 AM

Update
Stoploss Hit
Exit Price
₹347.1
Reputation: 6,068 • May 29 3:25 AM

buy cadilac above 350 target 355.65-360.2-365 stoploss 347.1
Like
Reply
Reputation: 3,179 • May 29 3:13 AM
Cadila Healthcare share price rises 3% on EIR from USFDA
The USFDA had conducted an inspection at the facility from 2 to 9 March, 2020.
Moneycontrol
Like
Reply
Reputation: 7,516 • May 29 5:39 AM
Like
Reply
Reputation: 3,179 • May 28 3:03 AM
link
Trade Setup for Friday: Top 15 things to know before Opening Bell
The key support level for Nifty is placed at 9,380.65, followed by 9,271.2. If the index moves up, key resistance levels to watch out for are 9,555.4 and 9,620.7.
Moneycontrol
Like
Reply
Reputation: -1,862 • May 28 4:25 AM

Type
Sell
Instrument
CADILAHC JUN20 FUT
Entry Price
₹339.9
Price@Trade
₹339.9
Target Price
₹320
Stop Price
₹351
Valid Till
Jun 4, 2020 3:20 AM
Margin
₹195,593.05 approx for 2200 Qty
Status
Exited
Exit Price
₹336
Net P&L
+₹8,580 (+4.39%)
Like
Reply (1)
Latest replies
Trading @Trading2020
May 28 6:52 AM

Update
Exited
Exit Price
₹336
Net P&L
+₹8,580 (+4.39%)

Type
Buy
Instrument
CADILAHC
Entry Price
₹338  ₹338.35
Price@Trade
₹338.6
Target Price
₹438
Stop Price
₹300
Valid Till
May 28, 2021 3:20 AM
Margin
₹33,835 approx for 100 Qty
Status
Exited
Exit Price
₹348.35
Net P&L
+₹1,000 (+2.96%)
Like
Reply (3)
Latest replies

Update
Entry Price Modified
Price @ Update
₹338.35
Original Entry Price
₹338
New Entry Price
₹338.35
TrackerBot @trackerbot
May 28 3:32 AM

Update
Trade Entered
Entry Price
₹338.35

Update
Exited
Exit Price
₹348.35
Net P&L
+₹1,000 (+2.96%)
Reputation: 9,406 • May 26 5:07 AM

Type
Sell
Instrument
CADILAHC MAY20 FUT
Entry Price
₹344.45
Price@Trade
₹344.45
Target Price
₹330.8
Stop Price
₹348.8
Valid Till
May 28, 2020 3:20 AM
Margin
₹203,687.25 approx for 2200 Qty
Status
Exited
Exit Price
₹343.7
Net P&L
+₹1,650 (+0.81%)
Like
Reply (1)
Latest replies
Sam Sir @samsirs
May 26 6:47 AM

Update
Exited
Exit Price
₹343.7
Net P&L
+₹1,650 (+0.81%)
Reputation: 1,131 • May 26 2:54 AM

26-05-20 Intraday BUY CADILAHC in cash
only Above @ 350.50 #CADILAHC
Like
Reply (1)
Latest replies
Sameer  @tradingfab
May 26 3:03 AM

high 351.85 🔥🔥🔥
Reputation: 1,590 • May 25 5:58 AM

CADILAHC - chart - 824461
Resistance zone at
1st @359
2nd @397
Support 314
If price break resistance @359 then,
We will go long position, with 390+ target
Stop loss 345
5
Reply

*Performance for the WEEK*
*Notional accruals for the WEEK ₹ 1,54,495*
*Futures & Options educational trades for the week 18.5.20 to 22.5.20*
(My trade rules apply).
#stockmarket
The below trades are given for *educational* purposes and i am not responsible for any losses or pro...
Read more...
4
Reply
Reputation: 6,068 • May 22 3:16 AM

Type
Buy
Instrument
CADILAHC MAY20 FUT
Entry Price
₹350
Price@Trade
₹350
Target Price
₹356
Stop Price
₹348.45
Valid Till
May 22, 2020 3:20 AM
Margin
₹200,585 approx for 2200 Qty
Status
Stoploss Hit
Exit Price
₹348.45
Net P&L
-₹3,410 (-1.7%)
buy cadilac above 351.5 targfet 356-360.5-365.2 stoploss 348.45
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
May 22 3:21 AM

Update
Stoploss Hit
Exit Price
₹348.45
Reputation: 6,068 • May 22 3:15 AM

buy cadilac above 351.5 targfet 356-360.5-365.2 stoploss 348.45
Like
Reply
Reputation: 1,131 • May 22 3:06 AM

22-05-20 Intraday BUY CADILAHC in cash
only Above @ 349 #CADILAHC
Like
Reply (1)
Latest replies
Sameer  @tradingfab
May 22 3:14 AM

high 350.45 🔥🔥
A
Reputation: -18 • May 22 2:59 AM

Type
Buy
Instrument
CADILAHC
Entry Price
₹338.3
Price@Trade
₹345.85
Target Price
₹349.1
Stop Price
₹335.3
Valid Till
Jun 1, 2020 3:20 AM
Margin
₹33,830 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹335.3
Net P&L
-₹300 (-0.89%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
May 26 7:10 AM

Update
Trade Entered
Entry Price
₹338.3
TrackerBot @trackerbot
May 26 7:41 AM

Update
Stoploss Hit
Exit Price
₹335.3
Reputation: 7,516 • May 21 4:19 AM
Like
Reply
Reputation: 3,179 • May 21 12:18 PM
COVID-19 fight | Zydus Cadila supplies 30,000 test kits to ICMR
These test kits have been manufactured in partnership with ICMR-NIV of Pune for surveillance purposes, the company said.
Moneycontrol
1
Reply

CADILAHC - chart - 816575
Cadila trade going on
bought at 335
target 375
shared with everyone
1
Reply
somiish shukkla in CADILAHC
#CADILAHC opened O=L at 339.50 to 350 done till...

#CADILAHC opened O=L at 339.50 to 350 to 352 all target done high made 353. 10:48 / 21-May
Like
Reply

Type
Buy
Instrument
CADILAHC
Entry Price
₹351
Price@Trade
₹350.8
Target Price
₹356
Stop Price
₹348
Valid Till
May 21, 2020 3:20 AM
Margin
₹526,500 approx for 1500 Qty
Status
Stoploss Hit
Exit Price
₹348
Net P&L
-₹4,500 (-0.85%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
May 21 4:10 AM

Update
Trade Entered
Entry Price
₹351
TrackerBot @trackerbot
May 21 4:34 AM

Update
Stoploss Hit
Exit Price
₹348

Type
Sell
Instrument
CADILAHC MAY20 310 PE
Entry Price
₹1.35
Price@Trade
₹1.35
Target Price
₹0.05
Stop Price
₹2.5  ₹1.2
Valid Till
May 28, 2020 3:20 AM
Margin
₹259,206.4 approx for 2200 Qty
Status
Target Achieved
Exit Price
₹0.05
Net P&L
+₹2,860 (+1.1%)
Like
Reply (2)
Latest replies

Update
Stoploss Trailed
Price @ Update
₹0.65
Original SL
₹2.5
New SL
1.2
TrackerBot @trackerbot
May 28 3:41 AM

Update
Target Achieved
Exit Price
₹0.05

Type
Sell
Instrument
CADILAHC MAY20 FUT
Entry Price
₹348.65
Price@Trade
₹348.65
Target Price
₹345
Stop Price
₹350
Valid Till
May 21, 2020 3:20 AM
Margin
₹199,640.22 approx for 2200 Qty
Status
Stoploss Hit
Exit Price
₹350
Net P&L
-₹2,970 (-1.49%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
May 21 3:52 AM

Update
Stoploss Hit
Exit Price
₹350

Type
Buy
Instrument
CADILAHC
Entry Price
₹348
Price@Trade
₹349
Target Price
₹388
Stop Price
₹308
Valid Till
Jun 19, 2020 3:20 AM
Margin
₹69,600 approx for 200 Qty
Status
Exited
Exit Price
₹348.5
Net P&L
+₹100 (+0.14%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
May 21 3:06 AM

Update
Trade Entered
Entry Price
₹348

Update
Exited
Exit Price
₹348.5
Net P&L
+₹100 (+0.14%)
somiish shukkla in CADILAHC
#CADILAHC is good to buy above 337 for 340, 34...

#CADILAHC opened O=L at 339.50 to 350 done till now. 9:32 / 21-May will it or not do last target of 352
Like
Reply
somiish shukkla in CADILAHC
#CADILAHC is good to buy above 337 for 340, 34...

#CADILAHC opened O=L at 339.50 to 346 done till now. 9:21 / 21-May
Like
Reply
ElliottWave Master in CADILAHC
#CADILAHC Chart Analysis.

#CADILAHC Can Show a Big Move, Add It To Your WatchList
2
Reply
3
Reply

#CADILAHC is good to buy above 337 for 340, 343, 350 & 352 Sell only below 330
Like
Reply

Type
Sell
Instrument
CADILAHC MAY20 FUT
Entry Price
₹336  ₹336.3
Price@Trade
₹335.7
Target Price
₹330
Stop Price
₹338
Valid Till
May 20, 2020 3:20 AM
Margin
₹191,301 approx for 2200 Qty
Status
Stoploss Hit
Exit Price
₹338
Net P&L
-₹3,740 (-1.96%)
Like
Reply (4)
Latest replies

Update
Entry Price Modified
Price @ Update
₹336.1
Original Entry Price
₹336
New Entry Price
₹336.1

Update
Entry Price Modified
Price @ Update
₹336.05
Original Entry Price
₹336.1
New Entry Price
₹336.05
TrackerBot @trackerbot
May 20 8:12 AM

Update
Trade Entered
Entry Price
₹336.3
TrackerBot @trackerbot
May 20 8:17 AM

Update
Stoploss Hit
Exit Price
₹338

Type
Buy
Instrument
CADILAHC MAY20 FUT
Entry Price
₹332
Price@Trade
₹331.55
Target Price
₹342
Stop Price
₹322
Valid Till
May 20, 2020 3:20 AM
Margin
₹190,613.69 approx for 2200 Qty
Status
Exited before entry
Like
Reply (1)
Latest replies

Update
Exited before entry
Price @ Update
₹328.55

Type
Buy
Instrument
CADILAHC MAY20 FUT
Entry Price
₹325.95
Price@Trade
₹325.95
Target Price
₹332
Stop Price
₹320
Valid Till
May 19, 2020 3:20 AM
Margin
₹575,735.59 approx for 6600 Qty
Status
Exited
Exit Price
₹328.85
Net P&L
+₹19,140 (+3.32%)
Like
Reply (1)
Latest replies

Update
Exited
Exit Price
₹328.85
Net P&L
+₹19,140 (+3.32%)

FUTURE
SELL CADILAHC BELOW 323 TGT OPEN
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • CADILAHC - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization35,491.84
    Enterprise Value38,320.54
    Price to Earnings35.57
    Price to Book Value3.96
    Return on Capital Employed0.15
    Return on Equity0.14
    Face Value1
    Dividend Yield0.01
  • CADILAHC - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    8-May-20Prabhudas LilladherSell263
    7-Apr-20Karvy Stock BrokingBuy362
    7-Feb-20Karvy Stock BrokingBuy316
    6-Feb-20Motilal OswalBuy317
    3-Feb-20Nirmal BangBuy314
    CADILAHC Brokerage Price Target
  • CADILAHC Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jun 5364.85367.55357.7359.7
    Jun 4358364.05353.35362.7
    Jun 3355.55359.4351.75353.8
    Jun 2350.9364.5350.45353.05
    Jun 1345.9352.85342.65349.55
  • CADILAHC Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹339.17
    30 Day Moving Average₹335.56
    50 Day Moving Average₹321.36
    100 Day Moving Average₹293.19
    200 Day Moving Average₹267.6
  • CADILAHC - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue5,8093,230.70.8
    Operating Profit1,646321.14.13
    Profit Before Tax1,497642.21.33
    Net Income1,090661.90.65
  • CADILAHC - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds8,9567,7450.16
    Total Liabilities4,5364,4840.01
    Total Assets13,49212,2300.1
  • CADILAHC - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity2891,291.9-0.78
    Cash from Investing Activity26-2,904.5-1.01
    Cash from Financing Activity-1481,365.6-1.11
    Net Cash Flow167-247-1.68
  • CADILAHC - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.090.06
    Return on Equity0.140.1
    Return on Capital Employed0.150.07
  • CADILAHC - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.1
    3 Year CAGR Growth in Operating Profit0.07
    3 Year CAGR Growth in EBIDTA0.08
    3 Year CAGR Growth in Net Income-0.14
    3 Yr CAGR Growth - Diluted EPS-0.83
  • CADILAHC - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.65
    5 Year CAGR Growth in Operating Profit1.33
    5 Year CAGR Growth in EBIDTA1.44
    5 Year CAGR Growth in Net Income1.19
    3 Yr CAGR Growth - Diluted EPS-0.56
  • CADILAHC - Recent News

    keyboard_arrow_down
    NewsBot
    Today 4:28 AM
    ICMR validates three IgG Elisa test kits to be used in sero-survey
    Moneycontrol
    NewsBot
    May 29 3:13 AM
    Cadila Healthcare share price rises 3% on EIR from USFDA
    Moneycontrol
    NewsBot
    May 21 12:18 PM
    COVID-19 fight | Zydus Cadila supplies 30,000 test kits to ICMR
    Moneycontrol
    NewsBot
    May 7 8:23 AM
    In race to get COVID-19 vaccine, are we setting the bar low?
    Moneycontrol
    NewsBot
    May 7 6:28 AM
    Pharma index up 45% from March lows; CLSA says earnings momentum to continue, raises targets
    Moneycontrol
    NewsBot
    Apr 30 1:58 AM
    India exports 50 million hydroxychloroquine tablets to US for COVID-19 fight: Source
    Moneycontrol
    NewsBot
    Apr 28 8:08 AM
    Experts say these 7 stocks are a good long-term bet amid virus-led crisis
    Moneycontrol
    NewsBot
    Apr 26 2:53 AM
    'Redemption pressure in high-risk, high-return funds may hit mid, smallcaps'
    Moneycontrol
    NewsBot
    Apr 20 4:03 AM
    Department of Biotechnology approves funding for 3 companies for developing COVID-19 vaccine
    Moneycontrol
    NewsBot
    Apr 20 7:18 AM
    Cadila Healthcare says exploring cancer, hepatitis drug Interferon alpha-2b for COVID-19
    Moneycontrol
  • CADILAHC - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • CADILAHC - More Information

    keyboard_arrow_down

    Cadila HealthcareLtd:
    Cadila Healthcare Limited is associated with researching, producing, developing, marketing and distributing pharmaceutical products in India and several other countries like Spain, South Africa, France as well as Latin American countries. It offers a wide range of products, including wellness products, active pharmaceutical ingredients, human dosage formulations, vaccines, animal healthcare products, and biosimilars.
    Apart from this, the company offers several other products in various medical aspects of pain-management, gastrointestinal therapy, gynaecology, dermatology, respiratory issues, etc. Among some of its famous products are, Glucon-D (glucose power, EverYuth in their skincare products range, Sugar-Free and Nycil (prickly heat talc).
    Additionally, Cadila has ongoing development of 21 biosimilars along with six different novel products. It also has drugs in multiple aspects for treatment of autoimmune diseases, cancer, diseases concerned with ophthalmology, hepatology, nephrology, rheumatology and several infectious diseases. It also associates itself with retail pharmacy, labour supply along with administration activities. Cadila is an Ahmedabad based company in India and was incorporated back in 1952.
    About Company Information:
    In 1996, Cadila Healthcare Ltd launched Falcigo through a strategic alliance agreement with a China-based company named Gulin Pharma. In MAY, 2000 Cadila had a helping hand for strengthening its southern market by acquiring Recon Ltd. In the following year, the company acquired German Remedies. This newly acquired company was the top M&A company in the pharmaceutical sector in India.
    In the same year, 2001, Cadila entered into an alliance with Oncova with the aim of running research together in the aspect of Oncogenomics. The next year, in 2002, the company went on to acquire Banyan Chemicals. In the following year, in 2003, Zydus Pathline, German Remedies, Zoom Properties and Recon Healthcare, all of them merged with Cadila Healthcare Ltd.
    In 2005, Cadila Healthcare Ltd. entered into a strategic agreement with Mallinckrodt Pharmaceuticals Generics. This was a strategic alliance for marketing products launched by Mallinckrodt through one of their business units, under a single joint label.In 2005 itself, the company wished to cater to international needs by manufacturing active pharmaceutical ingredients and cytotoxic drugs along with injectables, for this purpose it signed a fifty-fifty joint agreement with Mayne Pharma, an Australia based company.
    During 2005-2006 the company signed an agreement with Bharat Serums and Vaccines Ltd. These two companies came together to form Zydus BSV Pharma Private Limited for developing, manufacturing and marketing proprietary Novel Drug Delivery System that would sell anti-cancer goods in international markets.
    During 2007-2008, Cadila launched two new divisions, namely, Fortiza and Corza, while focusing on restructuring their existing Alidac division. In February of 2008, in the aspect of research in drug discovery and their development, Cadila went into a 3-year contract with a Swedish company Karo Bio.
    On the 28th of January in 2011, Bayer Healthcare had signed an agreement with Cadila for setting up Bayer Zydus Pharma which will be responsible for selling pharmaceutical products in India. Each of these two companies entering the alliance were to hold 50 of shares each and have equal representation on the board, Bayer Zydus was headquartered in Mumbai.
    On 25th of July, 2013, Cadila along with a non-profit organization based in Seattle, named IDRI, declared that these two organizations would collaborate for clinical development of IDRI’s VL vaccine for attacking parasites. It was also agreed upon that Cadila would also be responsible for producing this product.
    On the 31st of December, 2015, the company informed that the USFDA sent a letter of warning for the company’s Ahmedabad active pharmaceutical ingredients facility and its Moraiya formulation. In February of 2016, the company informed that it was permitted by the USFDA for marketing Doxycycline Capsules USP, 100 mg, 50 mg, and 75 mg.
    On the 28th of March, 2016, Cadila announced that its subsidiary company Zydus was all set to acquire Actibile from a company named Albert David Ltd. This brand of the drug is for gastroenterology aspect and also used for treating stones in the gallbladder.
    How Cadila HealthcareLtd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Cadila Healthcare Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Cadila HealthcareLtd, Competitors and Sector Peers:
    Aarey Drugs & Pharmaceuticals Ltd. AARDRU
    Aarti Drugs Ltd. AARTDR
    Aayush Food & Herbs Ltd. AAYFOO
    Abbott India Ltd. ABBIND
    ABL Bio-Technologies Ltd. ABLBIO
    Addlife Pharma Ltd. ADDPHA
    Bacil Pharma Ltd. BACPHA
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Brooks Laboratories Ltd. BROLAB
    Cipla Ltd. CIPLTD
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    Dujohn Laboratories Ltd. DUJLAB
    Earum Pharmaceuticals Ltd.
    Elder Health Care Ltd. ELDHEA
    Elder Pharmaceuticals Ltd. ELDPHA
    Elegant Pharmaceuticals Ltd. ELEPHA
    Gennex Laboratories Ltd. GENLAB
    Genomics Biotech Ltd. GENBIO
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    JK Pharmachem Ltd. JKPHAL
    Jubilant Life Sciences Ltd. JUBILO
    Jupiter Bioscience Ltd. JUPIBI
    Lupin Ltd. LUPLTD
    Lyka Labs Ltd. LYKLAB
    Novartis India Ltd. NOVAIN
    Ortin Laboratories Ltd. ORTLAB
    Piramal Enterprises Ltd. NICPIR
    Piramal Phytocare Ltd. PIRLIF
    Ranbaxy Laboratories Ltd. RANLAB
    Sanjivani paranteral Ltd. SANPAR
    Sanofi India Ltd. AVEPHA
    Sarvodaya Labs Ltd. SARLAB
    Sun Pharmaceutical Industries Ltd. SUN28
    TTK Healthcare Ltd. TTKHEA
    Venmax Drugs & Pharmaceuticals Ltd. YENDRU
    Venus Remedies Ltd. VENREM
    Zenith Healthcare Ltd. ZENHEA
    Zenlabs Ethica Ltd. SHRLAK
    Zenotech Laboratories Ltd. ZENLAB
    Zim Laboratories Ltd. ZIMLAB
    Zora Pharma Ltd.[Amalgamated] ZORPHA
    Zota Healthcare Ltd. ZOTHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020